MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
375.92%
Quick Ratio
375.92%
Cash Ratio
61.70%
Debt to Asset Ratio
65.96%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term marketable securities
    • Operating lease, right-of-use as...
    • Cash and cash equivalents
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Liability related to the sale of...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
33,419
34,928
37,437
32,298
Short-term marketable securities
156,087
128,846
148,412
156,566
Accounts receivable
6,534
7,809
8,493
6,882
Prepaid expenses and other current assets
7,579
6,810
4,342
8,590
Income tax receivable
-
19
-
0
Short-term restricted cash
-
-
-
0
Total current assets
203,619
178,412
198,684
204,336
Property and equipment
-
-
-
59,200
Less accumulated depreciation and amortization
-
-
-
23,805
Long-term marketable securities
21,987
63,238
56,055
-
Property and equipment, net
31,942
33,114
34,308
35,395
Operating lease, right-of-use assets
35,852
36,436
37,003
37,549
Long-term restricted cash
3,360
3,360
3,360
3,360
Other long-term assets
110
144
93
92
Total assets
296,870
314,704
329,503
280,732
Accounts payable
3,293
4,363
1,885
1,948
Accrued expenses and other current liabilities
10,183
6,859
7,575
12,751
Liability related to the sale of future royalties
36,784
31,461
31,981
30,710
Operating lease liabilities
3,906
3,759
3,287
3,146
Total current liabilities
54,166
46,442
44,728
48,555
Liability related to the sale of future royalties, net of current portion
88,289
97,309
102,822
111,132
Operating lease liabilities, net of current portion
51,750
52,777
53,782
54,757
Series 1 nonconvertible preferred stock
1,311
1,311
1,311
1,311
Other long-term liabilities
286
278
269
260
Total liabilities
195,802
198,117
202,912
216,015
Common stock 0.01 par value per share, 100,000 shares authorized 29,120 and 21,387 shares issued and outstanding at june 30, 2026 and september 30, 2025 respectively
291
291
290
214
Additional paid-in capital
551,163
546,988
543,497
469,771
Accumulated other comprehensive loss
-927
-734
-329
-339
Accumulated deficit
-449,459
-429,958
-416,867
-404,929
Total stockholders' equity
101,068
116,587
126,591
64,717
Total liabilities and stockholders' equity
296,870
314,704
329,503
280,732
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term marketablesecurities$156,087K (-2.02%↓ Y/Y)Cash and cashequivalents$33,419K (-25.42%↓ Y/Y)Prepaid expenses andother current assets$7,579K (-25.99%↓ Y/Y)Accounts receivable$6,534K (-21.59%↓ Y/Y)Total current assets$203,619K (-8.57%↓ Y/Y)Operating lease,right-of-use assets$35,852K (-6.27%↓ Y/Y)Property and equipment,net$31,942K (-12.77%↓ Y/Y)Long-term marketablesecurities$21,987K Long-term restricted cash$3,360K (0.00%↑ Y/Y)Other long-termassets$110K (17.02%↑ Y/Y)Total assets$296,870K (-1.38%↓ Y/Y)Total liabilities andstockholders' equity$296,870K (-1.38%↓ Y/Y)Total liabilities$195,802K (-11.70%↓ Y/Y)Total stockholders'equity$101,068K (27.48%↑ Y/Y)Accumulated deficit-$449,459K (-16.37%↓ Y/Y)Accumulated othercomprehensive loss-$927K (-130.60%↓ Y/Y)Liability related to thesale of future...$88,289K (-26.39%↓ Y/Y)Total currentliabilities$54,166K (21.59%↑ Y/Y)Operating leaseliabilities, net of current...$51,750K (-7.02%↓ Y/Y)Series 1nonconvertible preferred stock$1,311K (-2.89%↓ Y/Y)Other long-termliabilities$286K (13.49%↑ Y/Y)Additional paid-in capital$551,163K (18.35%↑ Y/Y)Common stock 0.01 parvalue per share,...$291K (35.98%↑ Y/Y)Liability related to thesale of future...$36,784K (32.53%↑ Y/Y)Accrued expenses andother current...$10,183K (-6.17%↓ Y/Y)Operating leaseliabilities$3,906K (63.16%↑ Y/Y)Accounts payable$3,293K (-7.16%↓ Y/Y)

ENANTA PHARMACEUTICALS INC (ENTA)

ENANTA PHARMACEUTICALS INC (ENTA)